Exelixis conducted the STELLAR-305 trial, investigating zanzalintinib and pembrolizumab, while Robert Burns maintained a Buy rating.
1 report, 1 independent
Updated Aug 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Exelixis conducted the STELLAR-305 trial, investigating zanzalintinib and pembrolizumab, while Robert Burns maintained a Buy rating.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Exelixis
American biotechnology company
Nothing else this week.
-
Robert Burns
National security reporter -- Associated Press
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyH.C. Wainwright Maintains Buy on Exelixis (EXEL) Despite STELLAR-305 Phase 3 Setback Exelixis, Inc. (NASDAQ:EXEL) is one of the best growth stocks to buy according to analysts. On August 12, H.C. Wai